News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
297,395 Results
Type
Article (14587)
Company Profile (102)
Press Release (282706)
Section
Business (96674)
Career Advice (582)
Deals (17569)
Drug Delivery (66)
Drug Development (39457)
Employer Resources (60)
FDA (7261)
Job Trends (6815)
News (165096)
Policy (15107)
Tag
Academia (546)
Alliances (25730)
Alzheimer's disease (423)
Approvals (7284)
Artificial intelligence (101)
Bankruptcy (153)
Best Places to Work (4923)
Breast cancer (76)
Cancer (606)
Cardiovascular disease (54)
Career advice (489)
Cell therapy (110)
Clinical research (33047)
Collaboration (305)
Compensation (134)
COVID-19 (835)
C-suite (90)
Data (583)
Diabetes (74)
Diagnostics (1810)
Drug pricing (63)
Earnings (35828)
Events (41915)
Executive appointments (313)
FDA (7631)
Funding (201)
Gene therapy (94)
GLP-1 (327)
Government (1387)
Healthcare (4574)
Infectious disease (866)
Inflammatory bowel disease (54)
Interviews (72)
IPO (7075)
Job creations (2130)
Job search strategy (440)
Layoffs (181)
Legal (3646)
Lung cancer (83)
Lymphoma (55)
Manufacturing (131)
Medical device (2405)
Medtech (2408)
Mergers & acquisitions (10678)
Metabolic disorders (221)
Neuroscience (601)
NextGen: Class of 2025 (2019)
Non-profit (773)
Northern California (749)
Obesity (128)
Opinion (121)
Patents (85)
People (30188)
Pharmaceutical (64)
Phase I (8802)
Phase II (14097)
Phase III (12301)
Pipeline (309)
Postmarket research (1450)
Preclinical (3528)
Radiopharmaceuticals (121)
Rare diseases (152)
Real estate (2847)
Regulatory (10799)
Research institute (644)
Resumes & cover letters (99)
Southern California (663)
Startups (1755)
United States (6895)
Vaccines (145)
Weight loss (87)
Date
Today (50)
Last 7 days (249)
Last 30 days (1150)
Last 365 days (14358)
2025 (1797)
2024 (14448)
2023 (16409)
2022 (22367)
2021 (23204)
2020 (21874)
2019 (17271)
2018 (13540)
2017 (15366)
2016 (14526)
2015 (17287)
2014 (13651)
2013 (11705)
2012 (12773)
2011 (13306)
2010 (12088)
Location
Africa (348)
Asia (21434)
Australia (2956)
California (1687)
Canada (871)
China (194)
Colorado (81)
Connecticut (84)
Delaware (57)
Europe (42039)
Florida (271)
Illinois (191)
Indiana (125)
Japan (73)
Kansas (58)
Maryland (261)
Massachusetts (1391)
Minnesota (94)
New Jersey (680)
New York (454)
North Carolina (348)
Northern California (749)
Ohio (54)
Pennsylvania (408)
South America (538)
Southern California (663)
Texas (246)
Virginia (57)
Washington State (139)
297,395 Results for "vertex pharmaceuticals incorporated".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pain
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
February 18, 2025
·
3 min read
·
Tristan Manalac
Pain
Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks
Vertex expects to make the newly approved non-opioid pain medicine Journavx available by the end of February.
February 11, 2025
·
2 min read
·
Tristan Manalac
Legal
HHS Says Vertex is ‘Grasping at Straws’ With Casgevy Fertility Suit
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes.
January 16, 2025
·
2 min read
·
Tristan Manalac
Pain
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy
Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their concerns as the company’s share price fell 13% in premarket trading.
December 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Vertex to Participate in Upcoming March Investor Conferences
February 18, 2025
·
2 min read
Approvals
Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.
December 23, 2024
·
2 min read
·
Nick Paul Taylor
Genetown
Vertex to Participate in Upcoming June Investor Conferences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
May 22, 2024
·
2 min read
Sickle cell disease
Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024
Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026.
December 9, 2024
·
2 min read
·
Tristan Manalac
Business
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for type 1 diabetes.
April 23, 2024
·
4 min read
Earnings
Vertex Tops Q3 Forecast on Strength of Cystic Fibrosis Sales, Raises Full-Year Revenue Guidance
Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid therapy suzetrigine in pain—both slated for January 2025.
November 5, 2024
·
2 min read
·
Tristan Manalac
1 of 29,740
Next
